Nagi Bioscience

Executive Summary

Nagi Bioscience, a Swiss biotechnology company founded in 2019, has developed an automated in vivo testing platform utilizing the nematode C. elegans to accelerate research in aging, longevity, and age-related diseases. The platform enables high-throughput, simultaneous measurement of lifespan, healthspan, and biological age, offering significant advantages over traditional mammalian models in terms of speed, cost, and ethical considerations. Nagi serves biotech, pharma, and nutraceutical clients through both on-site instrumentation and contract research services, positioning itself as a key enabler in the growing field of geroscience. The aging research market is expanding rapidly, driven by increasing focus on healthy lifespan extension and the development of interventions for age-related conditions. Nagi's technology addresses a critical bottleneck in the field by providing a scalable, standardized, and automated solution for in vivo testing. With its unique value proposition and early-mover advantage, the company is well-positioned to capture market share. However, adoption depends on validation by key opinion leaders and successful commercial deployments. The company's progress in securing partnerships and funding will be crucial for scaling operations and establishing credibility in a competitive landscape.

Upcoming Catalysts (preview)

• Q3 2026Series A financing round closure70% success
• H1 2027First major pharma partnership for aging research50% success
• Q4 2026Publication of validation data in a high-impact journal80% success